Safety, pharmacokinetics and quantitative EEG modulation of TAK‐071, a novel muscarinic M1 receptor positive allosteric modulator, in healthy subjects

• Published in: British journal of clinical pharmacology Vol. 88; no. 2; pp. 600 - 612
• Main Authors: Yin, Wei, Mamashli, Fahimeh, Buhl, Derek L., Khudyakov, Polyna, Volfson, Dmitri, Martenyi, Ferenc, Gevorkyan, Hakop, Rosen, Laura, Simen, Arthur A.
• Format: Journal Article
• Language: English
• Published: England John Wiley and Sons Inc 01.02.2022
• Subjects: Alzheimer's disease; Donepezil - adverse effects; Dose-Response Relationship, Drug; Double-Blind Method; Electroencephalography; electrophysiology; Healthy Volunteers; Humans; Original; Parkinson's disease; pharmacokinetic‐pharmacodynamic; phase I; Receptor, Muscarinic M1 - agonists; phase I; Parkinson's disease; pharmacokinetic-pharmacodynamic; electrophysiology; Alzheimer's disease

Aims TAK‐071 is a muscarinic M1 receptor positive allosteric modulator designed to have low cooperativity with acetylcholine. This was a first‐in‐human study to evaluate the safety, pharmacokinetics, and pharmacodynamics of TAK‐071. Methods TAK‐071 was administered as single and multiple doses in a...